Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Lancet

Volumn 352, Issue 9138, 1998, Pages 1426-1432

  Poynard, Thierry ^a,j   Marcellin, Patrick ^b   Lee, Samuel S ^k   Niederau, Christian ^c   Minuk, Gerald S ^d   Ideo, Gaetano ^e   Bain, Vincent ^k   Heathcote, Jenny ^f   Zeuzem, Stefan ^g   Trepo, Christian ^h   Albrecht, Janice ⁱ  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c University Heinrich Heine   (Germany)

^d UNIVERSITY OF MANITOBA   (Canada)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY HEALTH NETWORK   (Canada)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^h HÔTEL DIEU   (France)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

^j Serv d'Hepato Gastroenterologie G   (France)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BILIRUBIN; HEMOGLOBIN; PLACEBO; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; URIC ACID; VIRUS RNA;

ADULT; ADVERSE DRUG REACTION; AGE; AGED; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEMALE; FEMININITY; FIBROSIS; FOLLOW UP; GENOTYPE; HEMOLYSIS; HEPATITIS C; HUMAN; INSOMNIA; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RISK; STATISTICAL ANALYSIS; URIC ACID BLOOD LEVEL; VIRUS LOAD;

EID: 0032585237     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07124-4     Document Type: Article

References (27)

1. 1 Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26 (suppl 1): 62-65.
2. 2 WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-44.
3. 3 Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A non-B hepatitis. New Engl J Med 1992; 327: 1906-11.
4. 4 Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332: 1463-66.
5. 5 Poynard T, Bedossa P, Opolon P, for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-32.
6. 6 Darby SC, Ewart DW, Giangrande PLF, et al. Mortality from liver cancer and liver disease in haemophilic men and boys given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-31.
7. 7 Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic viral hepatitis. Viral Hepat Rev 1997; 2: 219-28.
8. 8 Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: effects of dose and duration. Hepatology 1996; 24: 778-89.
9. 9 Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C effects of dose increment and duration of treatment on response rates. Results of the first multicenter Australian trial. J Hepatol 1995; 23: 487-96.
10. 10 Poynard T, Bedossa P, Chevalier M, et al, and the multicentre study group. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non A, non B hepatitis. New Engl J Med 1995; 332: 1457-62.
11. 11 Patterson JL, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990; 12: 1332-46.
12. 12 Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1 the procoagulant fg1 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998; 160: 3487-93.
13. 13 DiBisceglie AM, Shindo M, Fong TL, et al. Pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-54.
14. 14 Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25: 591-98.
15. 15 Bodenheimer HC, Lindsay KL, Davis GL, et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-77.
16. 16 Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: interferon and ribavirin. J Hepatol 1997; 26 (suppl 1): 1085-115.
17. 17 Reichard O, Norkrans G, Fyden A, et al. Randomised, double-blind, placebo-controlled trial of interferon (-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
18. 18 Tong MJ, Hwang SJ, Lefkowitz M, et al. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin treatment with ribavirin. J Gastroenterol Hepatol 1994; 9: 587-91.
19. 19 Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterisation of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093-102.
20. 20 The METAVIR cooperative group. Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology 1994; 20: 15-20.
21. 21 Bedossa P, Poynard T for the French METAVIR group. An algorithm for the grading of activity in chronic hepatitis C. Hepatology 1996; 24: 289-93.
22. 22 Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-35.
23. 23 Lindsay KL. Therapy of chronic hepatitis C: overview. Hepatology 1997; 26 (suppl): 71-77.
24. 24 Gamma C, Giunta M, Linea C, Pagliaro L. The effect of interferon in chronic hepatitis C: a quantitative evaluation of histology by metaanalysis. J Hepatol 1997; 26: 1187-99.
25. 25 Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15: 1013-16.
26. 26 Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-81.
27. 27 Davis G, Esteban-Muir R, Rustgi V, et al. Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of relapse of chronic hepatitis C. N Engl J Med (in press).